Veru Inc
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 189
- Market Cap
- $122.9M
- Introduction
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
- Conditions
- Muscle LossObesity
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06282458
- Locations
- 🇺🇸
SKY Integrative Medical Center, Ridgeland, Mississippi, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Palm Research Center, Las Vegas, Nevada, United States
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Veru Inc.
- Registration Number
- NCT05079360
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸California Research Institute (CRI), Los Angeles, California, United States
🇺🇸Banner Health/ Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05065411
- Locations
- 🇺🇸
Lakes Research, Miami Lakes, Florida, United States
🇺🇸UPMC Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Banner MDACC, Gilbert, Arizona, United States
P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Veru Inc.
- Registration Number
- NCT05008510
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04869943
- Locations
- 🇺🇸
Banner Health/ Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Texas Oncology Sammons Cancer Center, Dallas, Texas, United States
🇺🇸University of Miami- Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent
- Conditions
- Metastatic Castration-resistant Prostate CancerAndrogen Resistant Prostatic Cancer
- Interventions
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT04844749
- Locations
- 🇺🇸
Tower Urology, Los Angeles, California, United States
🇺🇸Associated Urologists of North Carolina, Raleigh, North Carolina, United States
🇺🇸Comprehensive Urologic Care, Lake Barrington, Illinois, United States
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT04842747
- Locations
- 🇺🇸
Methodist Hospital, Saint Louis Park, Minnesota, United States
🇲🇽Hospital General de Culiacán, Culiacán, Mexico
🇧🇬Multiprofile Hospital for Active Treatment - Dr. Atanas Dafovski AD, Kardzhali, Department of Pneumology and Phthisiatry, Dept. of Pneumology & Phthisiatry, Kardzhali, Bulgaria
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04843319
- Locations
- 🇺🇸
Urology Associates of Southern Arizona, Tucson, Arizona, United States
🇺🇸Chesapeake Urology Research Associates, Towson, Maryland, United States
🇺🇸Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04388826
- Locations
- 🇺🇸
Methodist Hospital, Saint Louis Park, Minnesota, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
🇺🇸Memorial Hermann Memorial City Hospital, Houston, Texas, United States
To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Veru Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03752099
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States
🇺🇸Urology of Virginia, Virginia Beach, Virginia, United States
🇺🇸Urology Clinics of North Texas, Dallas, Texas, United States